Generation of CART cells targeting oncogenic TROP2 for the elimination of epithelial malignancies

癌症研究 前列腺 血管生成 癌症 医学 内科学
作者
Darel Martínez Bedoya,T D King,Avery D. Posey
出处
期刊:Cytotherapy [Elsevier BV]
卷期号:21 (5): S11-S12 被引量:11
标识
DOI:10.1016/j.jcyt.2019.03.570
摘要

Background & Aim

TROP2 (also referred to as Tacstd2) is a membrane-associated glycoprotein highly expressed in many epithelial cancers, including oral, head-and-neck, thyroid, lung, esophageal, gastric, colorectal, pancreatic, breast, renal, uterine, cervical, ovarian, prostate, and glioma, and expression of TROP2 negatively correlates with prognosis and survival in many of these malignancies. TROP2 signaling supports tumor growth and progression through the induction of pathways controlling cell cycle progression, invasion and metastasis, proliferation, angiogenesis, cell growth and survival. In addition, tumor release of TROP2-containing exosomes can promote the migration of TROP2-negative tumor cells. Here, we generated several TROP-2-targeting CAR molecules and evaluated their activity as CART cells against various epithelial tumor cell lines.

Methods, Results & Conclusion

Single-chain variable fragments targeting TROP2 were produced through domain sequencing of hybridomas and through other publically available sources and cloned into lentiviral transfer plasmids containing second-generation CAR backbones. Transduction of human T cells routinely leads to the expression of >50% CAR+ cells, including the generation of TROP2-CART cells from T cells of a mTNBC patient. We evaluated interferon-gamma production as well as cytotoxicity of TROP2-CART cells cultured with TROP2+ breast, prostate and pancreatic tumor cells to choose a lead TROP2-CAR. In addition, we generated an isogenic TROP2- prostate cancer through Cas9-based gene editing and observed loss of cytotoxicity, demonstrating specificity of the TROP2-CART. However, TROP2-CART can kill TROP2- cells in the presence of TROP2+ cells, a feature also observed by CART19 when cultured with CD19+ and CD19- cells, consistent prior reports that activated CART cells induce tumor apoptosis through death receptors. Prior reports demonstrated that blockade of death receptor ligands abolished the non-specific cytotoxicity of CART19 cells, but this approach provided only partial blockade of TROP2-CART cytotoxicity. Instead, we describe and demonstrate a new mechanism by which transfer of TROP2+ tumor exosomes to TROP2- tumor cells increases the proportion of tumor targetable by TROP2-CART and may allow TROP2-CART to overcome the challenge of antigen heterogeneity in solid tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
1秒前
1秒前
莫愁完成签到,获得积分10
1秒前
SCI的芷蝶完成签到 ,获得积分10
1秒前
老朱发布了新的文献求助10
2秒前
zrj完成签到 ,获得积分10
2秒前
chen完成签到,获得积分10
2秒前
3秒前
蓝色的云完成签到,获得积分10
3秒前
小二郎应助完美的流沙采纳,获得10
4秒前
影子完成签到 ,获得积分10
4秒前
4秒前
4秒前
5秒前
七安完成签到,获得积分10
5秒前
轻松的惜芹应助不安雁开采纳,获得10
6秒前
爱学习的孩纸完成签到 ,获得积分10
6秒前
abala发布了新的文献求助10
6秒前
7秒前
bless完成签到,获得积分10
8秒前
彭于晏应助yyf采纳,获得10
8秒前
LiFeiYu完成签到,获得积分10
8秒前
9秒前
独特凡松发布了新的文献求助10
9秒前
搜集达人应助难过梦竹采纳,获得10
9秒前
Akim应助KYRIELIU采纳,获得10
10秒前
Owen应助任性若云采纳,获得10
10秒前
李大了发布了新的文献求助10
10秒前
ZDY完成签到,获得积分10
10秒前
10秒前
观妙散人发布了新的文献求助10
10秒前
赘婿应助高高紫烟采纳,获得10
11秒前
11秒前
隐形曼青应助林子青采纳,获得10
11秒前
深情安青应助冬去春来采纳,获得10
12秒前
12秒前
Erislastem发布了新的文献求助10
12秒前
彭于彦祖应助鱼咬羊采纳,获得30
12秒前
znn发布了新的文献求助10
13秒前
乐乐应助高工采纳,获得10
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974779
求助须知:如何正确求助?哪些是违规求助? 3519193
关于积分的说明 11197417
捐赠科研通 3255311
什么是DOI,文献DOI怎么找? 1797760
邀请新用户注册赠送积分活动 877150
科研通“疑难数据库(出版商)”最低求助积分说明 806187